Latest news
Vaxart Inc (VXRT) Advances COVID-19 Trial with Attractive Valuation Metrics - GuruFocusGuruFocus · Sat, 08 Aug 2026 03:40:15 GMTVXRT: Strong safety data, BARDA funding, and prudent financial strategy support pipeline progress - TradingViewTradingView · Fri, 07 Aug 2026 21:53:45 GMTVaxart (OTCMKTS:VXRT) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeatMarketBeat · Thu, 06 Aug 2026 23:19:23 GMTVaxart : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.commarketscreener.com · Thu, 06 Aug 2026 22:44:34 GMTVaxart Provides Business Update and Reports Second Quarter 2026 Financial Results - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 20:05:00 GMTHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Vaxart (VXRT) Investors: 5 Days to Application Deadline in Securities Fraud Class Action, Investors with Significant Losses Encouraged to Contact the Firm - TMX NewsfileTMX Newsfile · Sun, 02 Aug 2026 06:32:59 GMTVaxart, Inc. Actuals & Estimates (OTC:VXRT) - TradingViewTradingView · Sat, 01 Aug 2026 06:27:18 GMTEarnings Preview: Vaxart to Report Financial Results Post-market on August 06 - MoomooMoomoo · Sat, 01 Aug 2026 01:00:53 GMT